BG61729B1 - 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они - Google Patents

9-заместени-2-(2-норм-алкоксифенил)пурин-6-они Download PDF

Info

Publication number
BG61729B1
BG61729B1 BG100291A BG10029196A BG61729B1 BG 61729 B1 BG61729 B1 BG 61729B1 BG 100291 A BG100291 A BG 100291A BG 10029196 A BG10029196 A BG 10029196A BG 61729 B1 BG61729 B1 BG 61729B1
Authority
BG
Bulgaria
Prior art keywords
carbon atoms
straight
formula
branched chain
chain alkyl
Prior art date
Application number
BG100291A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100291A (bg
Inventor
Ulrich Niewoehner
Erwin Bischoff
Helmuth Schuetz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BG100291A publication Critical patent/BG100291A/bg
Publication of BG61729B1 publication Critical patent/BG61729B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BG100291A 1995-01-19 1996-01-18 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они BG61729B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (2)

Publication Number Publication Date
BG100291A BG100291A (bg) 1996-07-31
BG61729B1 true BG61729B1 (bg) 1998-04-30

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100291A BG61729B1 (bg) 1995-01-19 1996-01-18 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они

Country Status (30)

Country Link
US (1) US5866571A (cs)
EP (1) EP0722943A1 (cs)
JP (1) JPH08231546A (cs)
KR (1) KR960029335A (cs)
CN (1) CN1138583A (cs)
AR (1) AR002704A1 (cs)
AU (1) AU4097796A (cs)
BG (1) BG61729B1 (cs)
BR (1) BR9600149A (cs)
CA (1) CA2167349A1 (cs)
CO (1) CO4700524A1 (cs)
CZ (1) CZ16896A3 (cs)
DE (1) DE19501480A1 (cs)
EE (1) EE9600020A (cs)
FI (1) FI960226A7 (cs)
HR (1) HRP960009A2 (cs)
HU (1) HUP9600107A3 (cs)
IL (1) IL116771A (cs)
MA (1) MA23779A1 (cs)
NO (1) NO960221L (cs)
NZ (1) NZ280829A (cs)
PE (1) PE10597A1 (cs)
PL (1) PL312353A1 (cs)
SG (1) SG47379A1 (cs)
SK (1) SK7696A3 (cs)
SV (1) SV1996000004A (cs)
TN (1) TNSN96005A1 (cs)
TR (1) TR199600701A2 (cs)
YU (1) YU2896A (cs)
ZA (1) ZA96399B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
WO2003053975A1 (en) * 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
PE10597A1 (es) 1997-06-13
NO960221D0 (no) 1996-01-18
MA23779A1 (fr) 1996-10-01
NZ280829A (en) 1998-04-27
YU2896A (sh) 1999-03-04
CO4700524A1 (es) 1998-12-29
EE9600020A (et) 1996-08-15
HRP960009A2 (en) 1997-12-31
JPH08231546A (ja) 1996-09-10
EP0722943A1 (de) 1996-07-24
AR002704A1 (es) 1998-04-29
IL116771A (en) 1999-06-20
PL312353A1 (en) 1996-07-22
CA2167349A1 (en) 1996-07-20
NO960221L (no) 1996-07-22
ZA96399B (en) 1996-08-14
DE19501480A1 (de) 1996-07-25
SV1996000004A (es) 1997-02-19
FI960226A7 (fi) 1996-07-20
BR9600149A (pt) 1998-01-06
HU9600107D0 (en) 1996-03-28
FI960226A0 (fi) 1996-01-17
SG47379A1 (en) 1998-04-17
TNSN96005A1 (en) 2005-03-15
CZ16896A3 (en) 1996-08-14
IL116771A0 (en) 1996-05-14
SK7696A3 (en) 1996-08-07
KR960029335A (ko) 1996-08-17
HUP9600107A3 (en) 1999-06-28
AU4097796A (en) 1996-07-25
TR199600701A2 (tr) 1996-08-21
HUP9600107A2 (en) 1997-05-28
CN1138583A (zh) 1996-12-25
BG100291A (bg) 1996-07-31
US5866571A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
US11001563B2 (en) SSAO inhibitor
EP2183253B1 (en) Thieno-pyridine derivatives as mek inhibitors
EP0591528B1 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
US5290782A (en) Xanthine derivatives
CA2237221C (en) Protein kinase c inhibitor
US8487101B2 (en) Thieno-pyridine derivatives as MEK inhibitors
ES2948793T3 (es) Acidos cicloheptílicos como antagonistas de LPA
AU720305B2 (en) Purin-6-one derivatives
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
BG100291A (bg) 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они
KR102834472B1 (ko) 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
RS62597B1 (sr) Jedinjenje pirazol-oksazolidinona protiv virusa hepatitisa b
JP2021513530A (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
US5284837A (en) Derivatives of purine, process for their preparation and a pharmaceutical preparation
JP2011504164A (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
EP1597234B1 (en) Novel compounds
EP0319170A2 (en) Acyl derivatives of hydroxy pyrimidines
EP1065209B1 (fr) Nouveaux inhibiteurs de métalloprotéases, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2007039580A1 (en) Imidazolyl-substituted benzophenone compounds
CN117164590B (zh) 稠合嘧啶类衍生物及其应用
US7317030B2 (en) Compounds as inhibitors of cell proliferation and viral infections
CN118930552A (zh) 异苯并呋喃-1(3h)-酮类化合物及其制备方法、药物组合物和用途
EP1568696A1 (en) Compounds as inhibitors of cell proliferation and viral infections
WO2009037302A1 (en) 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors